Sysmex’s PA-100 AST System dramatically cuts the time needed for UTI diagnosis to just 15 minutes and identifies the most effective antibiotic within 30 minutes. A recent budget impact analysis suggests potential cost savings for healthcare systems, based on projected data from Spain.

PARIS, April 01, 2025 — Sysmex’s PA-100 AST System is changing how urinary tract infections (UTIs) are diagnosed and treated. By using advanced nanofluidic technology combined with rapid antimicrobial susceptibility testing (AST), the system delivers practical results in under 45 minutes, eliminating delays caused by traditional lab methods. This improvement allows healthcare providers to make faster, more informed decisions, leading to better patient care.

UTIs Affect Millions Worldwide
UTIs are very common, affecting over 400 million people each year. Delays in getting a diagnosis and the common practice of using general antibiotics often lead to poorer outcomes, further infections, and increased antimicrobial resistance (AMR).
With a reported sensitivity of 84% and specificity of 99%, the PA-100 AST System accurately detects infections and enables targeted antibiotic prescriptions, which reduces the unnecessary use of broad-spectrum antibiotics. This is a significant advancement in combating AMR. Providing clinicians with fast and accurate diagnostic information revolutionizes UTI treatment, benefiting patients and making healthcare systems more financially stable.

A recent budget impact model indicates that integrating the PA-100 AST System into Spanish public healthcare could lead to significant cost savings in managing UTIs. The analysis estimates potential savings of around €323 million in the first year, assuming full adoption, with continued cost reductions expected over three years. These savings are projected to come from fewer secondary complications, reduced hospital admissions, and lower indirect costs.

PA-100 AST System Wins Longitude Prize
Earlier this year, the PA-100 AST System received the prestigious Longitude Prize, an £8 million award recognizing innovations that tackle antimicrobial resistance. This award highlights the system’s ability to improve patient outcomes and lessen the global AMR crisis, along with its economic and clinical value.
For more information about the PA-100 AST System and its technology, .

About Sysmex Europe SE
Sysmex Europe, a subsidiary of the Sysmex Corporation, supports healthcare professionals and patients in the EMEA region by offering a wide array of medical diagnostic products and solutions. Our comprehensive solutions include instruments, high-quality reagents, software, and dependable service and support, all designed to improve the healthcare experience for everyone.

Contact:
Vivien Busse
pr@sysmex-europe.com

“`